Art. -Nr.: HY-B0249

Didanosine

(Synonyms: 2',3'-Dideoxyinosine; ddI)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Didanosine (2',3'-Dideoxyinosine; ddI) is a a potent and orally active dideoxynucleoside analogue, and also is a potent nucleoside reverse transcriptase inhibitor. Didanosine shows antiretroviral activity for HIV.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.45%
CAS. Nr.: 69655-05-6
Formel: C₁₀H₁₂N₄O₃
Molecular Weight:236.23

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Didanosine Chemical Structure

CAS. Nr.: 69655-05-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
C8166	IC₅₀	1 μM Compound: DDI	Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain	10.1016/0960-894X(95)00257-T
C8166	CC₅₀	9 mM Compound: DDI	Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line	10.1016/0960-894X(95)00257-T
C8166	EC₅₀	0.9 μM Compound: ddl	Compound was evaluated for the inhibition of p24 viral antigen production in C-8166 cells. Compound was evaluated for the inhibition of p24 viral antigen production in C-8166 cells.	10.1016/0960-894X(95)00585-H
CCRF-CEM	CC₅₀	>250 μM Compound: ddI	Cytotoxicity against CEM cells Cytotoxicity against CEM cells	[PMID: 17321639]
CCRF-CEM	EC₅₀	4.6 μM Compound: ddI	Antiviral activity against HIV1 3B in CEM cells Antiviral activity against HIV1 3B in CEM cells	[PMID: 17321639]
CCRF-CEM	CC₅₀	>250 μM Compound: Ddi	Cytotoxicity against HIV-infected human CEM cells Cytotoxicity against HIV-infected human CEM cells	[PMID: 18420310]
CCRF-CEM	EC₅₀	4.6 μM Compound: Ddi	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 18420310]
CCRF-CEM	CC₅₀	>250 μM Compound: 1j; ddI	Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days	[PMID: 32515595]
CCRF-CEM	CC₅₀	>100 μg/mL Compound: didanosine	Cytotoxic concentration required to reduce CEM cell viability by 50% Cytotoxic concentration required to reduce CEM cell viability by 50%	[PMID: 8709116]
CEM-SS	IC₅₀	>100 mM Compound: DDI	Concentration of compound required to 50% growth inhibition of HIV-1 in CEM-SS cells Concentration of compound required to 50% growth inhibition of HIV-1 in CEM-SS cells	[PMID: 1901911]
CEM-V	CC₅₀	>10 μM Compound: DDI	Cytotoxic concentration required to reduce the viability of mock-infected CEM-V cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected CEM-V cells by 50%	[PMID: 9240351]
CEM-V	EC₅₀	2.8 μM Compound: DDI	Inhibition of HIV-1 replication in CEM-V cells Inhibition of HIV-1 replication in CEM-V cells	[PMID: 9240351]
H9	EC₅₀	0.0056 μM Compound: ddI	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.0056 μM Compound: ddI	Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
HeLa	IC₅₀	2.3 μM Compound: ddI	Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	4.6 μM Compound: ddI	Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	6.3 μM Compound: ddI	Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	8.3 μM Compound: ddI	Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	CC₅₀	>50 μM Compound: Dideoxyinosine	Cytotoxicity against mock-infected human HeLa cells by MTT assay Cytotoxicity against mock-infected human HeLa cells by MTT assay	[PMID: 25682562]
HepG2	EC₅₀	>10 μM Compound: 11 beta-Ld2I	Antiviral activity against Hepatitis B virus in 2.2.15 cell line Antiviral activity against Hepatitis B virus in 2.2.15 cell line	10.1016/0960-894X(96)00293-4
HepG2	IC₅₀	>200 μM Compound: 11 beta-Ld2I	Concentration required to inhibit 50% of 2.2.15 cell line Concentration required to inhibit 50% of 2.2.15 cell line	10.1016/0960-894X(96)00293-4
MT2	IC₅₀	0.49 μM Compound: ddI	Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication	[PMID: 19596885]
MT4	CC₅₀	>100 μg/mL Compound: ddI	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	11 μg/mL Compound: ddI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	2.1 μg/mL Compound: ddI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	IC₅₀	2.71 μM Compound: DDI	Concentration required to protect the cell against HIV-2 strain ROD viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-2 strain ROD viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	IC₅₀	5.37 μM Compound: DDI	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	IC₅₀	7.15 μM Compound: DDI	Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells	[PMID: 15149669]
MT4	CC₅₀	≥529 μM Compound: DDI	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	IC₅₀	2.71 μM Compound: DDI	Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	5.37 μM Compound: DDI	Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	≥529 μM Compound: DDI	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	2.71 μM Compound: DDI	Antiviral activity against HIV2 ROD in human MT4 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV2 ROD in human MT4 cells assessed as inhibition of viral replication by MTT assay	[PMID: 17869386]
MT4	IC₅₀	5.37 μM Compound: DDI	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of viral replication by MTT assay	[PMID: 17869386]
MT4	CC₅₀	≥529 μM Compound: DDI	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 17869386]
MT4	IC₅₀	2.71 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	5.37 μM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	CC₅₀	≥529 μM Compound: DDI	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18692274]
MT4	IC₅₀	5.5 μM Compound: DDI	Ability to block replication of HIV-1 virus in mock infected MT-4 cells Ability to block replication of HIV-1 virus in mock infected MT-4 cells	[PMID: 1956037]
MT4	CC₅₀	1053 μM Compound: DDI	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1995896]
MT4	IC₅₀	5.5 μM Compound: DDI	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.	[PMID: 1995896]
MT4	CC₅₀	>529 μM Compound: DDI	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20638854]
MT4	IC₅₀	2.71 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	IC₅₀	5.37 μM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	CC₅₀	>100 μg/mL Compound: ddI	Toxicity against human MT4 cells by MTT assay Toxicity against human MT4 cells by MTT assay	[PMID: 21658957]
MT4	IC₅₀	2.31 μg/mL Compound: ddI	Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 21658957]
MT4	IC₅₀	5.76 μg/mL Compound: ddI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 21658957]
MT4	CC₅₀	>211 μM Compound: DDI	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	16 μM Compound: DDI	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	8.86 μM Compound: DDI	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	CC₅₀	>500 μM Compound: ddI	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23419738]
MT4	EC₅₀	34.7 μM Compound: ddI	Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 23419738]
MT4	EC₅₀	7.8 μM Compound: ddI	Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 23419738]
MT4	CC₅₀	211.69 μM Compound: DDI	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	15.33 μM Compound: DDI	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	17.19 μM Compound: DDI	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	CC₅₀	>212 μM Compound: DDI	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	18 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	19 μM Compound: DDI	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	CC₅₀	>50 μM Compound: dideoxyinosine	Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay	[PMID: 24926807]
MT4	IC₅₀	10.8 μM Compound: dideoxyinosine	Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	IC₅₀	9.6 μM Compound: dideoxyinosine	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	CC₅₀	>211.66 μM Compound: DDI	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	23.2 μM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	44.91 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	>211.67 μM Compound: DDI	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 25537532]
MT4	EC₅₀	23.2 μM Compound: DDI	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	44.91 μM Compound: DDI	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	CC₅₀	>212 μM Compound: DDI	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	23198 nM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	2.27 μM Compound: Dideoxyinosine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	EC₅₀	2.56 μM Compound: Dideoxyinosine	Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	CC₅₀	>212 μM Compound: DDI	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	23 μM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	CC₅₀	>50 μM Compound: dideoxyinosine	Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay	[PMID: 25946116]
MT4	EC₅₀	10.8 μM Compound: dideoxyinosine	Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	9.6 μM Compound: dideoxyinosine	Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	CC₅₀	>211.66 μM Compound: DDI	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	75.99 μM Compound: DDI	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	82.12 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	CC₅₀	50 μg/mL Compound: Didanosine	Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 27105027]
MT4	IC₅₀	17.95 μg/mL Compound: Didanosine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 27105027]
MT4	CC₅₀	>212 μM Compound: Didanosine	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 27112451]
MT4	EC₅₀	23 μM Compound: Didanosine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27112451]
MT4	CC₅₀	>50 μg/mL Compound: DDI	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27214512]
MT4	EC₅₀	2.09 μg/mL Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	EC₅₀	3.78 μg/mL Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	CC₅₀	>212 μM Compound: DDI	Cytotoxicity against mock-infected human MT4 cells Cytotoxicity against mock-infected human MT4 cells	[PMID: 27234889]
MT4	EC₅₀	8.85 μM Compound: DDI	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	CC₅₀	>212 μM Compound: ddI	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28659246]
MT4	CC₅₀	>100 μM Compound: ddI	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 38954919]
MT4	CC₅₀	>425 μM Compound: ddI	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days) Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days)	[PMID: 7523675]
MT4	EC₅₀	10 μM Compound: ddI	Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 (4 days) Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 (4 days)	[PMID: 7523675]
MT4	EC₅₀	11 μM Compound: ddI	Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-2 (8 days) Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-2 (8 days)	[PMID: 7523675]
MT4	IC₅₀	23 μM Compound: ddI	Anti-Human immunodeficiency virus activity against MT-4 cells Anti-Human immunodeficiency virus activity against MT-4 cells	[PMID: 8426365]
MT4	IC₅₀	28 μM Compound: ddI	Effect of Coformycin on the Anti-HIV activity in MT-4 cells at 0.10 uM Effect of Coformycin on the Anti-HIV activity in MT-4 cells at 0.10 uM	[PMID: 8426365]
MT4	IC₅₀	30 μM Compound: ddI	Effect of Erythro-9-(2-Hydroxy-3-nonyl) adenine (EHNA) on the Anti-HIV activity in MT-4 cells at 0.10 uM Effect of Erythro-9-(2-Hydroxy-3-nonyl) adenine (EHNA) on the Anti-HIV activity in MT-4 cells at 0.10 uM	[PMID: 8426365]
MT4	IC₅₀	30 μM Compound: ddI	Effect of Phosphate buffered saline on the Anti-HIV activity in MT-4 cells Effect of Phosphate buffered saline on the Anti-HIV activity in MT-4 cells	[PMID: 8426365]
MT4	IC₅₀	31 μM Compound: ddI	Effect of Erythro-9-(2-Hydroxy-3-nonyl) adenine (EHNA) on the Anti-HIV activity in MT-4 cells at 1.0 uM Effect of Erythro-9-(2-Hydroxy-3-nonyl) adenine (EHNA) on the Anti-HIV activity in MT-4 cells at 1.0 uM	[PMID: 8426365]
MT4	IC₅₀	39 μM Compound: ddI	Effect of Coformycin on the Anti-HIV activity in MT-4 cells at 1.0 uM Effect of Coformycin on the Anti-HIV activity in MT-4 cells at 1.0 uM	[PMID: 8426365]
MT4	CC₅₀	>50 μg/mL Compound: DDN, DDI	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	10.1007/s00044-013-0567-7
MT4	IC₅₀	2.09 μg/mL Compound: DDN, DDI	Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	IC₅₀	3.78 μg/mL Compound: DDN, DDI	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	EC₅₀	0.46 μg/mL Compound: ddl	In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay	10.1016/0960-894X(95)00395-A
MT4	EC₅₀	13 μM Compound: ddl	Compound was evaluated for the inhibition of HIV-1 induced cytopathic effect in MT-4 cells. Compound was evaluated for the inhibition of HIV-1 induced cytopathic effect in MT-4 cells.	10.1016/0960-894X(95)00585-H
MT4	CC₅₀	>1000 μM Compound: ddl	Compound was evaluated for the concentration required to reduce the viability of MT-4 cells. Compound was evaluated for the concentration required to reduce the viability of MT-4 cells.	10.1016/0960-894X(95)00585-H
MT4	EC₅₀	10 μM Compound: ddI (table 3)	Dose required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Dose required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1	10.1016/0960-894X(96)00216-8
PBMC	IC₅₀	<5 μM Compound: 2a	Anti-HIV activity measured as the ability to inhibit HIV -1 p24 Gag protein production, using PHA/PBM system. Anti-HIV activity measured as the ability to inhibit HIV -1 p24 Gag protein production, using PHA/PBM system.	[PMID: 7707321]
PBMC	IC₅₀	0.04 mM Compound: 1, DDI, Didanosine	Antiviral activity against HIV-1 HTLV-3B infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA Antiviral activity against HIV-1 HTLV-3B infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA	10.1039/C4MD00003J
PBMC	IC₅₀	2.863 mM Compound: 1, DDI, Didanosine	Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA	10.1039/C4MD00003J
TZM	CC₅₀	>100 μM Compound: ddI	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38954919]
Vero	CC₅₀	>10 μg/mL Compound: ddI	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17046264]
WI-38	CC₅₀	>100 μM Compound: Didanosine	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	>100 μM Compound: Didanosine	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]
WISH	ED₅₀	792 μM Compound: DDI	Antiviral activity against vesicular stomatitis virus infected in human WISH cells Antiviral activity against vesicular stomatitis virus infected in human WISH cells	[PMID: 25515560]

In Vitro

Didanosine is converted by cellular enzymes to the active antiviral metabolite dideoxyadenosine triphosphate (dd-ATP) and the intracellular half life of dd-ATP varies from 8-24 hours^[1].
Didanosine shows antiretroviral activity with IC₅₀ value of 0.24-0.6 mg/L for HIV infection^[3].
Didanosine (5, 10, 50, 100 ug/ml; 24, 48 h) shows no significant inhibition of cell proliferation in IEC-6 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

IEC-6 cells
Concentration:

5, 10, 50, 100 ug/ml
Incubation Time:

24, 48 h
Result:

Did not show any significant inhibition of cell proliferation at either 24 h or 48 h.

Apoptosis Analysis^[2]

Cell Line:

IEC-6 cells
Concentration:

100 ug/ml
Incubation Time:

24 h
Result:

Induced apoptosis with the apoptosis rates of 4.7% to 7.4%.

In Vivo

Didanosine (100, 150 mg/kg; p.o.; daily for 7 days) decreases the length of duodenal and in jejunal villus in mouse^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

30-40 g, male swiss mice^[2]
Dosage:

100, 150 mg/kg
Administration:

P.o.; daily for 7 days
Result:

Caused significant reductions in duodenal and in jejunal villus length and significantly decreased ileal crypt depth.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 69655-05-6
Appearance Solid
Molecular Weight 236.23
Formel C₁₀H₁₂N₄O₃
Color White to off-white
SMILES

OC[C@@H]1CC[C@H](N2C3=C(N=C2)C(O)=NC=N3)O1
Synonyms

2',3'-Dideoxyinosine; ddI
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (423.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.2332 mL

21.1658 mL

42.3316 mL

5 mM

0.8466 mL

4.2332 mL

8.4663 mL

10 mM

0.4233 mL

2.1166 mL

4.2332 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (8.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Munir N.Nassar, et al. Analytical profiles of drug substances and excipients. Journals & Books, 1993, 185-227.

[2]. Braga Neto MB, et al. Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. BMC Gastroenterol. 2010 Aug 11;10:90. [Content Brief]

[3]. Caroline M. Perry, et al. Didanosine. Drugs, 1999, 58, 1099-1135.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.2332 mL	21.1658 mL	42.3316 mL	105.8291 mL
	5 mM	0.8466 mL	4.2332 mL	8.4663 mL	21.1658 mL
	10 mM	0.4233 mL	2.1166 mL	4.2332 mL	10.5829 mL
	15 mM	0.2822 mL	1.4111 mL	2.8221 mL	7.0553 mL
	20 mM	0.2117 mL	1.0583 mL	2.1166 mL	5.2915 mL
	25 mM	0.1693 mL	0.8466 mL	1.6933 mL	4.2332 mL
	30 mM	0.1411 mL	0.7055 mL	1.4111 mL	3.5276 mL
	40 mM	0.1058 mL	0.5291 mL	1.0583 mL	2.6457 mL
	50 mM	0.0847 mL	0.4233 mL	0.8466 mL	2.1166 mL
	60 mM	0.0706 mL	0.3528 mL	0.7055 mL	1.7638 mL
	80 mM	0.0529 mL	0.2646 mL	0.5291 mL	1.3229 mL
	100 mM	0.0423 mL	0.2117 mL	0.4233 mL	1.0583 mL

Keywords

Didanosine

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Didanosine

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

3D Diverse Fragment Library

MCE Kinase Hinge Binder Fragment Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Didanosine

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Didanosine

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

3D Diverse Fragment Library

MCE Kinase Hinge Binder Fragment Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Didanosine

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Didanosine Related Classifications

HY-B0249 Related Classifications